Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review
Essat M., Harnan S., Gomersall T., Tappenden P., Wong R., Pavord I., Lawson R., Everard ML.
<jats:p>The aim of this review was to evaluate the clinical effectiveness of fractional exhaled nitric oxide (<jats:italic>F</jats:italic><jats:sub>eNO</jats:sub>) measured in a clinical setting for the management of asthma in adults.</jats:p><jats:p>13 electronic databases were searched and studies were selected against predefined inclusion criteria. Quality assessment was conducted using QUADAS-2. Class effect meta-analyses were performed.</jats:p><jats:p>Six studies were included. Despite high levels of heterogeneity in multiple study characteristics, exploratory class effect meta-analyses were conducted. Four studies reported a wider definition of exacerbation rates (major or severe exacerbation) with a pooled rate ratio of 0.80 (95% CI 0.63–1.02). Two studies reported rates of severe exacerbations (requiring oral corticosteroid use) with a pooled rate ratio of 0.89 (95% CI 0.43–1.72). Inhaled corticosteroid use was reported by four studies, with a pooled standardised mean difference of −0.24 (95% CI −0.56–0.07). No statistically significant differences for health-related quality of life or asthma control were found.</jats:p><jats:p><jats:italic>F</jats:italic><jats:sub>eNO</jats:sub>guided management showed no statistically significant benefit in terms of severe exacerbations or inhaled corticosteroid use, but showed a statistically significant reduction in exacerbations of any severity. However, further research is warranted to clearly define which management protocols (including cut-off points) offer best efficacy and which patient groups would benefit the most.</jats:p>